Patent 11975027 was granted and assigned to ImmunityBio on May, 2024 by the United States Patent and Trademark Office.
Provided herein are pharmaceutical compositions comprising tumoricidal and/or antimicrobial components isolated from the supernatant of NK-92 cell medium and methods of using the compositions for killing cancer cells.